This study is testing a new oral medication called EPN-701 for people with calciphylaxis, a rare and painful skin condition. Currently, there isn't an approved treatment for calciphylaxis. This early study aims to see if EPN-701 is safe and effective in reducing pain and the size of skin lesions. You might receive EPN-701 or a placebo (a look-alike pill with no medicine). To join, you must be at least 18 years old, have a doctor's diagnosis of calciphylaxis with at least one skin ulcer, and provide your consent. The study plans to enroll 60 participants, but its current status is unclear.

Study design

This is a Phase 2, double-blind, randomized controlled trial. About 60 adult participants will be randomly assigned to receive either EPN-701 or a placebo for 24 weeks.

What's involved

You would take EPN-701 or a placebo orally once a day for 24 weeks. Your pain intensity and wound surface area will be measured at the beginning and at 24 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your pain intensity and wound surface area will be measured at 24 weeks, which is the end of the treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.